Onco Sec
Biotechnology, 24 N Main St, San Diego, California, 08534, United States, 51-200 Employees
Phone Number: 18*********
Who is ONCOSEC
OncoSec is a biotechnology company pioneering new technologies to stimulate the bodys immune system to target and attack cancer. Through its proprietary DNA gene transfer technology, Onco...
Read More
-
Headquarters: 24 N Main St, San Diego, California, 08534, United States
-
Date Founded: 2011
-
Employees: 51-200
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Punit Dhillon
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 54 |
Show More
OncoSec Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding OncoSec
Answer: OncoSec's headquarters are located at 24 N Main St, San Diego, California, 08534, United States
Answer: OncoSec's phone number is 18*********
Answer: OncoSec's official website is https://oncosec.com
Answer: OncoSec's revenue is $1 Million to $5 Million
Answer: OncoSec's SIC: 2834
Answer: OncoSec's NAICS: 54
Answer: OncoSec has 51-200 employees
Answer: OncoSec is in Biotechnology
Answer: OncoSec contact info: Phone number: 18********* Website: https://oncosec.com
Answer: OncoSec is a biotechnology company pioneering new technologies to stimulate the bodys immune system to target and attack cancer. Through its proprietary DNA gene transfer technology, OncoSec seeks to deliver safer and more effective cancer treatments that can provide long-term benefits for patients who have limited or no available treatment options. OncoSecs technology combines TAVOTM (tavokinogene telseplasmid), an intratumoral (IT) DNA plasmid-based interleukin-12 (IL-12) designed to achieve targeted and sustained delivery of IT IL-12. TAVO has demonstrated a local and systemic anti-tumor response in several clinical trials, including preliminary data in a registration directed Phase 2b trial KEYNOTE-695 for anti-PD-1 checkpoint refractory metastatic melanoma and the KEYNOTE-890 Phase 2 trial in metastatic triple-negative breast cancer (mTNBC). To date, preliminary study results have laid the groundwork for the expansion into new DNA-encoded therapeutic candidates and tumor indications. OncoSec plans to develop TAVO, along with other immunologic genes to treat other cancer indications. OncoSec has received both Orphan Drug and Fast-Track Designation by the U.S. Food & Drug Administration for TAVO in metastatic melanoma. NASDAQ: $ONCS
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month